Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.
Hariharan S, Whitfield BT, Pirozzi CJ, Waitkus MS, Brown MC, Bowie ML, Irvin DM, Roso K, Fuller R, Hostettler J, Dharmaiah S, Gibson EA, Briley A, Mangoli A, Fraley C, Shobande M, Stevenson K, Zhang G, Malgulwar PB, Roberts H, Roskoski M, Spasojevic I, Keir ST, He Y, Castro MG, Huse JT, Ashley DM. Hariharan S, et al. Among authors: keir st. bioRxiv [Preprint]. 2023 Apr 21:2023.04.20.537594. doi: 10.1101/2023.04.20.537594. bioRxiv. 2023. PMID: 37131619 Free PMC article. Updated. Preprint.
Repurposing Clemastine to Target Glioblastoma Cell Stemness.
Sun MA, Yang R, Liu H, Wang W, Song X, Hu B, Reynolds N, Roso K, Chen LH, Greer PK, Keir ST, McLendon RE, Cheng SY, Bigner DD, Ashley DM, Pirozzi CJ, He Y. Sun MA, et al. Among authors: keir st. Cancers (Basel). 2023 Sep 18;15(18):4619. doi: 10.3390/cancers15184619. Cancers (Basel). 2023. PMID: 37760589 Free PMC article.
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.
Hariharan S, Whitfield BT, Pirozzi CJ, Waitkus MS, Brown MC, Bowie ML, Irvin DM, Roso K, Fuller R, Hostettler J, Dharmaiah S, Gibson EA, Briley A, Mangoli A, Fraley C, Shobande M, Stevenson K, Zhang G, Malgulwar PB, Roberts H, Roskoski M, Spasojevic I, Keir ST, He Y, Castro MG, Huse JT, Ashley DM. Hariharan S, et al. Among authors: keir st. Nat Commun. 2024 Jan 25;15(1):730. doi: 10.1038/s41467-024-44932-w. Nat Commun. 2024. PMID: 38272925 Free PMC article.
The neo-open reading frame peptides that comprise the tumor framome are a rich source of neoantigens for cancer immunotherapy.
Martin MV, Aguilar-Rosas S, Franke K, Pieterse M, van Langelaar J, Schreurs RR, Bijlsma MF, Besselink MG, Koster J, Timens W, Khasraw M, Ashley DM, Keir ST, Ottensmeier CH, King EV, Verheij J, Waasdorp C, Valk PJM, Engels SA, Oostenbach E, van Dinter JT, Hofman DA, Mok JY, van Esch WJE, Wilmink H, Monkhorst K, Verheul HMW, Poel D, Hiltermann TJN, van Kempen LC, Groen HJ, Aerts JGJV, van Heesch S, Lowenberg B, Plasterk R, Kloosterman WP. Martin MV, et al. Among authors: keir st. Cancer Immunol Res. 2024 Apr 4. doi: 10.1158/2326-6066.CIR-23-0158. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38573707
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Blümel L, Maue M, Bartl J, Ahmadov U, Langini M, Meyer FD, Cole A, Cruz-Cruz J, Graef CM, Wölfl M, Milde T, Witt O, Erdreich-Epstein A, Leprivier G, Kahlert U, Stefanski A, Stühler K, Keir ST, Bigner DD, Hauer J, Beez T, Knobbe-Thomsen CB, Fischer U, Felsberg J, Hansen FK, Vibhakar R, Venkatraman S, Cheshier SH, Reifenberger G, Borkhardt A, Kurz T, Remke M, Mitra S. Marquardt V, et al. Among authors: keir st. J Immunother Cancer. 2023 Jan;11(1):e005871. doi: 10.1136/jitc-2022-005871. J Immunother Cancer. 2023. PMID: 36639156 Free PMC article.
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Wei S, Yin D, Yu S, Lin X, Savani MR, Du K, Ku Y, Wu D, Li S, Liu H, Tian M, Chen Y, Bowie M, Hariharan S, Waitkus M, Keir ST, Sugarman ET, Deek RA, Labrie M, Khasraw M, Lu Y, Mills GB, Herlyn M, Wu K, Liu L, Wei Z, Flaherty KT, Abdullah K, Zhang G, Ashley DM. Wei S, et al. Among authors: keir st. Clin Cancer Res. 2022 May 13;28(10):2180-2195. doi: 10.1158/1078-0432.CCR-21-0833. Clin Cancer Res. 2022. PMID: 35247901 Free PMC article.
A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas.
Yu S, Wei S, Savani M, Lin X, Du K, Mender I, Siteni S, Vasilopoulos T, Reitman ZJ, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, Charbonneau CM, Sugarman E, Bowie M, Hariharan S, Waitkus M, Jiang W, McLendon RE, Pan E, Khasraw M, Walsh KM, Lu Y, Herlyn M, Mills G, Herbig U, Wei Z, Keir ST, Flaherty K, Liu L, Wu K, Shay JW, Abdullah K, Zhang G, Ashley DM. Yu S, et al. Among authors: keir st. Clin Cancer Res. 2021 Dec 15;27(24):6800-6814. doi: 10.1158/1078-0432.CCR-21-0374. Epub 2021 Sep 30. Clin Cancer Res. 2021. PMID: 34593527 Free PMC article.
MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.
Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ, Moure CJ, Hemphill C, Carpenter AB, Healy P, Ruger RC, Chen CJ, Greer PK, Zhao F, Spasojevic I, Grenier C, Huang Z, Murphy SK, McLendon RE, Friedman HS, Friedman AH, Herndon JE 2nd, Sampson JH, Keir ST, Bigner DD, Yan H, He Y. Hansen LJ, et al. Among authors: keir st. Cancer Res. 2019 Jul 1;79(13):3383-3394. doi: 10.1158/0008-5472.CAN-18-1010. Epub 2019 Apr 30. Cancer Res. 2019. PMID: 31040154 Free PMC article.
133 results